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To improve multidrug-resistant tuberculosis (MDR-TB)
detection, we successfully introduced the rpoB gene muta-
tion line probe assay into the national laboratory in Latvia,
a country with epidemic MDR-TB. The assay detected
rifampin resistance with 91% sensitivity and 96% specifici-
ty within 1 to 5 days (vs. 12–47 days for BACTEC). 
U
ntil recent years, global efforts to reduce the preva-
lence of multidrug-resistant tuberculosis (MDR-TB),
defined as in vitro resistance to at least rifampin and isoni-
azid, have focused on preventing new cases of acquired
MDR-TB. However, countries that already have a high
incidence of MDR-TB must implement additional strate-
gies, such as reducing transmission by detecting cases ear-
lier and improving infection control in settings with shared
air spaces. As yet undetermined are optimal methods to
identify drug-resistant Mycobacterium tuberculosis in a
timely and affordable way in resource-limited settings.
Standard laboratory methods of detecting drug resistance,
such as M. tuberculosis culture and drug susceptibility test-
ing (DST) performed with Löwenstein- Jensen (LJ) medi-
um, are inexpensive but slow; DST results are often not
available for 3 to 4 months. Testing methods that use liq-
uid media, such as BACTEC systems (Becton Dickinson,
Sparks, MD, USA), can deliver DST results to clinicians
within 3 to 4 weeks; however, this technology requires
expensive equipment and media.  
Several methods that work directly on respiratory spec-
imens and that detect resistance to a limited number of
drugs within 1 day to 3 weeks have been reported (1–5).
One assay that is commercially available is a line probe
assay, a reverse-hybridization assay that detects mutations
in the rpoB gene (5–12). Among clinical M. tuberculosis
isolates, those with mutations in the rpoB gene are associ-
ated with 80% to 90% rifampin resistance (5). Previously
published studies using this assay have demonstrated
90%–100% concordance when results are compared to
DST results among M. tuberculosis isolates from culture
and 78%–98% sensitivity and 84%–100% specificity
when applied to respiratory specimens that were positive
for acid-fast bacilli (AFB) (5–12). However, these studies
involved small numbers of respiratory specimens and were
not performed in a national TB laboratory that supports
diagnosis, treatment, and care for large numbers of MDR-
TB patients.
Latvia is among those countries with the highest preva-
lence of MDR-TB in the world (13). Rifampin resistance
in Latvia is closely associated with resistance to isoniazid;
therefore, detecting rifampin resistance should also detect
most MDR-TB cases (13). As part of a long-term project
to integrate new assays into the Latvian national laborato-
ry protocols to identify MDR-TB patients more quickly,
we prospectively compared the results of the line probe
assay for rpoB mutations to results with BACTEC DST
technology.
The Study 
We enrolled consecutive patients who were initially
seen at or referred to the Latvian State Centre of
Tuberculosis and Lung Diseases from January 2003 to
March 2004 with AFB-positive respiratory specimens
(sputum or bronchoalveolar lavage [BAL] specimens) and
identified as being at high risk for MDR-TB. Patients at
high risk were defined as those with a history of close con-
tact to a known MDR-TB patient or with a history of pre-
vious TB treatment (14).
After sputum specimens were decontaminated (15), we
tested for AFB (15) and set up 2 cultures for M. tuberculo-
sis: 1 in LJ medium (15) and 1 in either the BACTEC
Mycobacteria Growth Indicator Tube 960 or the BACTEC
460 system per manufacturer’s instructions (Becton
Dickinson). DNA was extracted from the remaining sus-
pension with the QIAAMP DNA Mini kit (Qiagen,
Valencia, CA, USA). Lysate was transferred to the line
probe kit INNO-LiPA Rif.TB (Innogenetics, Ghent,
Belgium) for amplification, including a second nested
reaction with inner primers and the hybridization reaction
(manufacturer’s instructions). In general, the rpoB gene
amplicons were incubated with immobilized, membrane-
bound rpoB gene probes, including overlapping wildtype
sequences (S1–S5) and 4 of the most frequent mutations
(R2:Asp516Val, R4a:His526Tyr, R4b:His526Asp, and
R5:Ser531Leu). The kit also includes a probe for M. tuber-
culosis complex. 
DST was performed with the BACTEC 460 system
(manufacturer’s protocols). We then compared line probe
results to M. tuberculosis culture and BACTEC DST
results for each patient. We also set up DST on LJ media
by using the proportion method (15). All laboratory testing
was performed at the Latvian State Centre of Tuberculosis
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*State Centre of Tuberculosis and Lung Diseases, Riga, Latvia;
and †Centers for Disease Control and Prevention, Atlanta,
Georgia, USAand Lung Diseases, Riga, Latvia. Line probe results were
not provided to physicians. Patient identifiers were
removed before analysis. The protocol underwent institu-
tional ethical review by the Latvian State Centre of
Tuberculosis and Lung Diseases, was determined not to be
human subjects research, and was approved as program-
matic evaluation by the Centers for Disease Control and
Prevention.
In total, 89 (37%) of 243 patients who met the case def-
inition for being at high risk for MDR-TB had AFB-posi-
tive respiratory specimens; 77 (87%) were sputum
specimens, and 12 (13%) were BAL specimens. M. tuber-
culosis isolates grew in BACTEC cultures from 86 (97%)
of the AFB-positive specimens. Mycobacteria other than
M. tuberculosis were identified in 3 of the remaining
BACTEC cultures. No dual infections were found. M.
tuberculosis complex was also detected by line probe
assay in 86 specimens, although for 2 patients M. tubercu-
losis grew in respiratory specimens in BACTEC cultures
but was not detected by the line probe assay, and 2 speci-
mens that were positive for M. tuberculosis complex by
line probe assay did not grow in BACTEC but did grow on
LJ media. These isolates were injected into the BACTEC
460 system for DST. The line probe assay correctly sepa-
rated  M. tuberculosis complex and nontuberculosis
mycobacteria.
The line probe assay had good sensitivity, high speci-
ficity, and positive predictive value and negative predictive
value for rifampin resistance compared to BACTEC
(Table 1). Among the isolates resistant to rifampin by
BACTEC DST, the rpoB mutations detected by the line
probe included 20 (61%) R5 (Ser531Leu), 8 (24%) R2
(Asp516Val), 1 (3%) R4b (His526Asp), and 1 (3%) ∆S5
(absence of hybridization to 1 wildtype sequence). One
rifampin BACTEC DST-susceptible isolate had a line
probe result read as ∆S1, ∆S2 (absence of hybridization to
2 wildtype sequences).
Most patients considered high risk for MDR-TB had
resistance to at least 1 drug (Table 2). Rifampin resistance
was highly correlated with classification as MDR-TB; 32
(97%) of 33 patients with rifampin resistance had MDR-
TB. The predictive value of the line probe rpoB mutation
result for MDR-TB was 91% (95% confidence interval
92–100). 
The line probe assay performed directly on DNA
extracted from respiratory specimens gave quicker results
for rifampin resistance (median = 4 days, range 1–5) than
other methods (BACTEC 460 median = 28 days, range
12–47; LJ median = 58 days, range 47–65). While DST
results from the BACTEC liquid culture system were
available considerably faster than were results from LJ
media, rpoB gene mutation results were available in <1
week.
Conclusions
In Latvia, where nearly 40% of patients had a history of
TB treatment and 10% of all new patients without a histo-
ry of treatment have MDR-TB (13,14), integrating a line
probe assay for rpoB gene mutations into regular laborato-
ry services could enhance MDR-TB control efforts.
Results from this study demonstrated that in persons con-
sidered at high risk for MDR-TB, the line probe assay
detected rifampin resistance with 91% sensitivity and 97%
specificity on respiratory specimens within 1 to 5 days of
specimen collection in a busy clinical laboratory.
Additionally, 91% of patients at high risk for MDR-TB,
with line probe assay results consistent with rpoB muta-
tions, were ultimately confirmed as having MDR-TB.
In addition, we compared the timeliness of acquiring
rifampin DSTresults between a liquid and solid media sys-
tem and a line probe assay. Although liquid media were
considerably faster than solid media, the line probe assay
for rpoB mutations performed directly on respiratory spec-
imens gave results consistent with MDR in <1 week.
Therefore, integrating the use of the line probe assay
on AFB-positive respiratory specimens into the Latvian
national laboratory could permit much earlier segregation
and isolation of infectious patients who have a high
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mission) and could facilitate more focused DST practices
for first- and second-line TB drugs and more efficient use
of resources. The high specificity is reassuring; the use of
line probe assay results to inform drug treatment selections
would rarely result in missed opportunities to treat with
rifampin. Conversely, only 9% of patients infected with a
rifampin-resistant isolate would not benefit from early
detection of resistance and would, in turn, receive care
similar to the current standard. 
Several other assays that detect drug resistance within 1
to 3 weeks have been described (1–5). Some of these may
perform as well as the line probe assay and be less expen-
sive. We chose the line probe assay for our project because
it was commercially available and had been evaluated by
several investigators (5–12). Also, the equipment and
skills could be applied toward other molecular epidemio-
logic studies to better understand ongoing transmission of
MDR-TB in Latvia. We will evaluate the cost-effective-
ness of integrating this assay into the Latvian State Centre
of Tuberculosis and Lung Diseases and may also model the
cost of new assays as they become available. This study,
part of a larger project to reduce the prevalence of MDR-
TB in Latvia, is a first step in identifying optimal methods
to identify drug-resistant M. tuberculosis in a timely and
affordable way in resource-limited settings with high
MDR-TB prevalence. 
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